Monitor for any subsequent conversion to a Schedule 13D if the investor's intent changes, though the current filing explicitly disclaims activist intent. The post-IPO lock-up period and insider trading restrictions may limit near-term share sales.
Price Chart
Executive Summary
Laurence W. Lytton filed a Schedule 13G disclosing a 7.4% passive stake in Retension Pharmaceuticals, Inc., consisting of 617,207 shares of common stock acquired as of October 13, 2026. The filing is a new position and certifies no intent to influence control, making it a routine passive disclosure.
Key Financial Metrics
Key Facts
- Laurence W. Lytton reported beneficial ownership of 617,207 shares of Retension Pharmaceuticals common stock.
- The stake represents 7.4% of shares outstanding, based on 8,331,599 shares post-IPO as stated in the filing.
- The filing is a new Schedule 13G, indicating a passive investment with no intent to influence or change control.
- The shares were acquired on or before October 13, 2026, the closing date of the issuer's IPO.
Financial Impact
7.4% stake valued at approximately $[undisclosed] based on post-IPO share price; no transaction price disclosed.
Risk Factors
- Passive stake disclosure — no immediate catalyst for stock price movement.
- Potential overhang if the investor decides to reduce the position after lock-up expiration, though no such intent is indicated.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000935836-26-000533 |
| Document: 0000935836-26-000533-index.html | 0000935836-26-000533 |
| Document: 0000935836-26-000533.txt | 0000935836-26-000533 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $15.25 | awaiting T+5 | — | $14.24 (−6.62%) |
Oct 16, 2026 10d ago | SC 13G | $16.33 $14.65 | ▼ −10.29% | ▼ −10.14% | $14.24 (−12.80%) |
Oct 16, 2026 10d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $14.24 (+1.21%) |
Oct 15, 2026 11d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.24 (+16.63%) |
Oct 14, 2026 12d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.24 (+16.63%) |
Oct 13, 2026 13d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.24 (+22.34%) |
Oct 13, 2026 13d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.24 (+22.34%) |
Oct 9, 2026 17d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $14.24 (+25.80%) |
Oct 9, 2026 17d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.24 (+35.23%) |
Oct 8, 2026 17d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.24 (+35.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers